News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Ember Therapeutics Broadens Brown Fat Small Molecule Drug Discovery Portfolio, Secures Exclusive License Options to Intellectual Property for Three Small Molecule Targets


10/4/2012 10:10:55 AM

BOSTON--(BUSINESS WIRE)--Ember Therapeutics, Inc., a company harnessing breakthroughs in brown fat biology and insulin sensitization to revolutionize the treatment of metabolic disease, today announced that it has secured exclusive option rights to intellectual property for three key small molecule targets – retinaldehyde dehydrogenase 1 (Aldh1a1), thioesterase superfamily member 1 (Them1), and TRPV4.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES